Ovid Therapeutics Inc. (OVID) Reaches $11.08 After 7.00% Up Move; Plancorp Lowered Its Johnson & Johnson (JNJ) Holding

December 5, 2017 - By Louis Casey

Plancorp Llc decreased Johnson & Johnson (JNJ) stake by 12.81% reported in 2017Q2 SEC filing. Plancorp Llc sold 3,037 shares as Johnson & Johnson (JNJ)’s stock rose 6.85%. The Plancorp Llc holds 20,662 shares with $2.73M value, down from 23,699 last quarter. Johnson & Johnson now has $375.33B valuation. The stock increased 0.50% or $0.7 during the last trading session, reaching $139.71. About 5.00 million shares traded. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since December 5, 2016 and is uptrending. It has underperformed by 4.16% the S&P500.

The stock of Ovid Therapeutics Inc. (NASDAQ:OVID) is a huge mover today! The stock increased 1.79% or $0.19 during the last trading session, reaching $11.08. About 93,427 shares traded or 75.68% up from the average. Ovid Therapeutics Inc. (NASDAQ:OVID) has 0.00% since December 5, 2016 and is . It has underperformed by 16.70% the S&P500.The move comes after 9 months positive chart setup for the $272.61 million company. It was reported on Dec, 5 by Barchart.com. We have $11.86 PT which if reached, will make NASDAQ:OVID worth $19.08M more.

Investors sentiment decreased to 0.83 in 2017 Q2. Its down 0.03, from 0.86 in 2017Q1. It fall, as 50 investors sold JNJ shares while 878 reduced holdings. 105 funds opened positions while 667 raised stakes. 1.73 billion shares or 0.03% less from 1.73 billion shares in 2017Q1 were reported. Ameriprise Financial Incorporated holds 17.86M shares or 1.18% of its portfolio. Letko Brosseau Inc reported 631,466 shares. St Germain D J has invested 2.6% in Johnson & Johnson (NYSE:JNJ). Todd Asset Mngmt Ltd Liability holds 0.02% or 6,458 shares. Hartline holds 1,566 shares or 0.07% of its portfolio. Rosenbaum Jay D has 2.74% invested in Johnson & Johnson (NYSE:JNJ) for 10,465 shares. Fcg Limited Liability reported 1.79% of its portfolio in Johnson & Johnson (NYSE:JNJ). Moreover, Live Your Vision Limited Liability Corp has 0.04% invested in Johnson & Johnson (NYSE:JNJ) for 908 shares. Bluefin Trading Ltd reported 0.13% of its portfolio in Johnson & Johnson (NYSE:JNJ). Wells Fargo Company Mn holds 0.96% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 22.62 million shares. Mutual Of Omaha Bank Wealth Mngmt has invested 1.69% in Johnson & Johnson (NYSE:JNJ). Arrowgrass Cap Ptnrs (Us) Limited Partnership reported 33,484 shares. 2,715 are owned by Oberweis Asset Management. Moreover, Sprucegrove Inv Ltd has 1.8% invested in Johnson & Johnson (NYSE:JNJ). 49,441 are held by Meiji Yasuda Life.

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on January, 23. They expect $1.72 EPS, up 8.86% or $0.14 from last year’s $1.58 per share. JNJ’s profit will be $4.62B for 20.31 P/E if the $1.72 EPS becomes a reality. After $1.90 actual EPS reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -9.47% negative EPS growth.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 13 have Buy rating, 5 Sell and 5 Hold. Therefore 57% are positive. Johnson & Johnson had 83 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Johnson & Johnson (NYSE:JNJ) earned “Buy” rating by RBC Capital Markets on Wednesday, October 18. Wells Fargo maintained Johnson & Johnson (NYSE:JNJ) on Wednesday, October 18 with “Buy” rating. The firm earned “Buy” rating on Friday, September 22 by RBC Capital Markets. BMO Capital Markets maintained the stock with “Buy” rating in Monday, July 10 report. As per Monday, August 31, the company rating was downgraded by Vetr. The stock of Johnson & Johnson (NYSE:JNJ) earned “Buy” rating by UBS on Tuesday, September 22. As per Monday, October 9, the company rating was upgraded by Wells Fargo. Citigroup maintained Johnson & Johnson (NYSE:JNJ) rating on Monday, October 23. Citigroup has “Buy” rating and $149 target. RBC Capital Markets maintained the stock with “Outperform” rating in Wednesday, July 20 report. Goldman Sachs maintained Johnson & Johnson (NYSE:JNJ) rating on Wednesday, April 20. Goldman Sachs has “Neutral” rating and $114 target.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com